StockpollyBeta
Get App
Popularity #3,451
ANL · NASDAQ · Biotechnology

Adlai Nortye (ADR) (ANL)

Develops clinical-stage cancer therapies targeting RAS pathways and immune responses.

$16.60
After hours+0.04 (+0.24%)
At close$16.56(+6.36%)

In millions of USD, except per-share figures

In millionsQ3 FY22Sep 2022Q4 FY22Dec 2022Q1 FY23Mar 2023Q2 FY23Jun 2023Q3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue000030003377
Gross profit000030003377
282815171520151511111010
Research & development16161314151513139977
332355222233
General & administrative332355222233
Other expenses9900−50−1−10000
Operating income−19−19−15−17−18−20−15−15−8−8−3−3
−3−30−4755110000
Interest income000000000000
Interest expense000000000000
Other non-operating income0004600000000
Income before tax−22−22−15−63−13−15−14−14−9−9−3−3
Income tax expense000000000000
Net income from continuing operations−22−22−15−63−13−15−14−14−9−9−3−3
Net income−22−22−15−63−13−15−14−14−9−9−3−3
EPS, basic−$2.61−$2.61−$1.77−$7.47−$1.95−$2.25−$1.59−$1.59−$0.81−$0.81−$0.17−$0.17
EPS, diluted−$2.61−$2.61−$1.77−$7.47−$1.95−$2.25−$1.59−$1.59−$0.81−$0.81−$0.17−$0.17
Weighted average shares, basic8888779911111616
Weighted average shares, diluted8888779911111616
EBITDA−19−19−14−63−17−20−14−14−8−8−3−3
Depreciation & amortization001100000000
EBIT−19−19−15−63−18−20−15−15−8−8−3−3